BAFFR-CAR T cells not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL”In the company’s words, NCT04690595 on ClinicalTrials.gov
- Tested for
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Main trialPhase 1
- “A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia”In the company’s words, NCT04690595 on ClinicalTrials.gov
Other drugs for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up2
- 18 NovPhase 1 trial completes · ClinicalTrials.gov
- 13 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 18 Nov 2026 | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | |
| Phase 1Recruiting | 13 Jul 2027 | BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026